Literature DB >> 9777948

Characterization of monoclonal antibodies to calpain 3 and protein expression in muscle from patients with limb-girdle muscular dystrophy type 2A.

L V Anderson1, K Davison, J A Moss, I Richard, M Fardeau, F M Tomé, C Hübner, A Lasa, J Colomer, J S Beckmann.   

Abstract

Monoclonal antibodies were raised to two regions of calpain 3 (muscle-specific calcium-activated neutral protease), which is the product of the gene that is defective in limb-girdle muscular dystrophy type 2A. The antibodies produced characteristic patterns of bands on Western blots: normal calpain 3 protein was represented by bands at 94 kd, plus additional fragments at approximately 60 or 30 kd, according to the antibody used. Specificity was confirmed by the loss of all bands in patients with null gene mutations. The "normal" profile of bands was observed in muscle from 33 control subjects and 70 disease-control patients. Calpain 3 protein was found to be extremely stable in fresh human muscle, with full-size protein being detected 8 hours after the muscle had been removed. Blots of muscle from nine limb-girdle muscular dystrophy type 2A patients with defined mutations showed variation in protein expression, with seven showing a clear reduction in the abundance of protein detected. No simple relationship was found between the abundance and clinical severity. Two patients showed normal expression of the full-size 94 kd band accompanied by a clear reduction in the smaller fragments. This pattern was also observed in one patient with an undefined form of limb-girdle dystrophy. These results indicate that immunodiagnosis is feasible, but caution will need to be exercised with the interpretation of near-normal protein profiles.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9777948      PMCID: PMC1853046          DOI: 10.1016/S0002-9440(10)65661-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  36 in total

1.  Concomitant deficiency of beta- and gamma-sarcoglycans in 20 alpha-sarcoglycan (adhalin)-deficient patients: immunohistochemical analysis and clinical aspects.

Authors:  R Barresi; V Confalonieri; M Lanfossi; C Di Blasi; E Torchiana; R Mantegazza; L Jarre; N Nardocci; P Boffi; F Tezzon; A Pini; F Cornelio; M Mora; L Morandi
Journal:  Acta Neuropathol       Date:  1997-07       Impact factor: 17.088

2.  Muscle-specific calpain, p94, interacts with the extreme C-terminal region of connectin, a unique region flanked by two immunoglobulin C2 motifs.

Authors:  K Kinbara; H Sorimachi; S Ishiura; K Suzuki
Journal:  Arch Biochem Biophys       Date:  1997-06-01       Impact factor: 4.013

Review 3.  Structure and physiological functions of ubiquitous and tissue-specific calpain species. Muscle-specific calpain, p94, interacts with connectin/titin.

Authors:  H Sorimachi; S Kimura; K Kinbara; J Kazama; M Takahashi; H Yajima; S Ishiura; N Sasagawa; I Nonaka; H Sugita; K Maruyama; K Suzuki
Journal:  Adv Biophys       Date:  1996

4.  Early onset autosomal dominant myopathy with rigidity of the spine: a possible role for laminin beta 1?

Authors:  J Taylor; F Muntoni; S Robb; V Dubowitz; C Sewry
Journal:  Neuromuscul Disord       Date:  1997-06       Impact factor: 4.296

5.  Multiple independent molecular etiology for limb-girdle muscular dystrophy type 2A patients from various geographical origins.

Authors:  I Richard; L Brenguier; P Dinçer; C Roudaut; B Bady; J M Burgunder; R Chemaly; C A Garcia; G Halaby; C E Jackson; D M Kurnit; G Lefranc; C Legum; J Loiselet; L Merlini; A Nivelon-Chevallier; E Ollagnon-Roman; G Restagno; H Topaloglu; J S Beckmann
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

6.  Primary adhalinopathy (alpha-sarcoglycanopathy): clinical, pathologic, and genetic correlation in 20 patients with autosomal recessive muscular dystrophy.

Authors:  B Eymard; N B Romero; F Leturcq; F Piccolo; A Carrié; M Jeanpierre; H Collin; N Deburgrave; K Azibi; M Chaouch; L Merlini; C Thémar-Noël; I Penisson; M Mayer; O Tanguy; K P Campbell; J C Kaplan; F M Tomé; M Fardeau
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

7.  Abnormalities in alpha-, beta- and gamma-sarcoglycan in patients with limb-girdle muscular dystrophy.

Authors:  C A Sewry; J Taylor; L V Anderson; E Ozawa; R Pogue; F Piccolo; K Bushby; V Dubowitz; F Muntoni
Journal:  Neuromuscul Disord       Date:  1996-12       Impact factor: 4.296

8.  Absence of calpain 3 in a form of limb-girdle muscular dystrophy (LGMD2A).

Authors:  M J Spencer; J G Tidball; L V Anderson; K M Bushby; J B Harris; M R Passos-Bueno; H Somer; M Vainzof; M Zatz
Journal:  J Neurol Sci       Date:  1997-03-10       Impact factor: 3.181

9.  The molecular biology of LGMD2B--towards the identification of the LGMD gene on chromosome 2p13.

Authors:  K Bushby; R Bashir; S Keers; S Britton; M Zatz; M R Passos-Bueno; M Lovett; I Mahjneh; G Marconi; T Strachan
Journal:  Neuromuscul Disord       Date:  1996-12       Impact factor: 4.296

10.  Evidence for implication of muscle-specific calpain (p94) in myofibrillar integrity.

Authors:  S Poussard; M Duvert; D Balcerzak; S Ramassamy; J J Brustis; P Cottin; A Ducastaing
Journal:  Cell Growth Differ       Date:  1996-11
View more
  24 in total

1.  Disruption of excitation-contraction coupling and titin by endogenous Ca2+-activated proteases in toad muscle fibres.

Authors:  Esther Verburg; Robyn M Murphy; D George Stephenson; Graham D Lamb
Journal:  J Physiol       Date:  2005-03-03       Impact factor: 5.182

2.  Calpainopathy-a survey of mutations and polymorphisms.

Authors:  I Richard; C Roudaut; A Saenz; R Pogue; J E Grimbergen; L V Anderson; C Beley; A M Cobo; C de Diego; B Eymard; P Gallano; H B Ginjaar; A Lasa; C Pollitt; H Topaloglu; J A Urtizberea; M de Visser; A van der Kooi; K Bushby; E Bakker; A Lopez de Munain; M Fardeau; J S Beckmann
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

3.  Pathogenity of some limb girdle muscular dystrophy mutations can result from reduced anchorage to myofibrils and altered stability of calpain 3.

Authors:  Natalia Ermolova; Elena Kudryashova; Marino DiFranco; Julio Vergara; Irina Kramerova; Melissa J Spencer
Journal:  Hum Mol Genet       Date:  2011-05-30       Impact factor: 6.150

4.  Autolytic activation of calpain 3 proteinase is facilitated by calmodulin protein.

Authors:  Natalia Ermolova; Irina Kramerova; Melissa J Spencer
Journal:  J Biol Chem       Date:  2014-11-11       Impact factor: 5.157

5.  Multiplex Western blotting system for the analysis of muscular dystrophy proteins.

Authors:  L V Anderson; K Davison
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

6.  Endogenous calpain-3 activation is primarily governed by small increases in resting cytoplasmic [Ca2+] and is not dependent on stretch.

Authors:  Robyn M Murphy; Graham D Lamb
Journal:  J Biol Chem       Date:  2009-01-14       Impact factor: 5.157

Review 7.  [Limb girdle muscular dystrophies].

Authors:  J Finsterer
Journal:  Nervenarzt       Date:  2004-12       Impact factor: 1.214

8.  The effect of calpain 3 deficiency on the pattern of muscle degeneration in the earliest stages of LGMD2A.

Authors:  M Vainzof; F de Paula; A M Tsanaclis; M Zatz
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

9.  Taurine supplementation increases skeletal muscle force production and protects muscle function during and after high-frequency in vitro stimulation.

Authors:  Craig A Goodman; Deanna Horvath; Christos Stathis; Trevor Mori; Kevin Croft; Robyn M Murphy; Alan Hayes
Journal:  J Appl Physiol (1985)       Date:  2009-05-07

10.  Mutations of CAPN3 in Korean patients with limb-girdle muscular dystrophy.

Authors:  Jin-Hong Shin; Hyang-Suk Kim; Chang-Hoon Lee; Cheol-Min Kim; Kyu-Hyun Park; Dae-Seong Kim
Journal:  J Korean Med Sci       Date:  2007-06       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.